(firstQuint)Evaluation of the Safety of Lubiprostone in Pediatric Subjects Aged  6 Years to < 18 Years With Functional Constipation.

 To assess the long-term safety and tolerability of oral lubiprostone 12 or 24mcg capsules dosed twice daily (BID) when administered orally for 24 weeks in pediatric subjects with functional constipation.

 Evaluation of lubiprostone safety and tolerability is the primary objective in this study.

.

 Evaluation of the Safety of Lubiprostone in Pediatric Subjects Aged  6 Years to < 18 Years With Functional Constipation@highlight

A study of the safety of Lubiprostone in pediatric subjects aged 6 Years to < 18 years diagnosed with Functional Constipation